Why DaVita HealthCare (DVA) is a Top Growth Stock for the Long-Term

Company Overview - DaVita Inc. is a leading provider of dialysis services in the U.S. for patients suffering from chronic kidney failure, operating kidney dialysis centers and providing related medical services primarily in dialysis centers and contracted hospitals across the U.S. [10] - The company's services include outpatient dialysis services, hospital inpatient dialysis services, and ancillary services such as ESRD laboratory services and disease management services [10]. Investment Ratings - DaVita Inc. holds a Zacks Rank of 2 (Buy) and has a VGM Score of A, indicating strong potential for investment [11]. - The company is also considered a top pick for growth investors, with a Growth Style Score of B, forecasting year-over-year earnings growth of 13.6% for the current fiscal year [11]. Earnings Estimates - In the last 60 days, three analysts have revised their earnings estimates upwards for fiscal 2024, with the Zacks Consensus Estimate increasing by $0.39 to $9.62 per share [11]. - DaVita boasts an average earnings surprise of 29.4%, indicating a strong performance relative to expectations [11]. Conclusion - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, DaVita Inc. is recommended for investors' consideration [12].